Veeda Clinical Research IPO – Review, Bid, Size, Allotment, Subscription, GMP & RHP

Let’s have a detailed review of the company and analytics of the Veeda Clinical Research IPO release date, IPO offer price, subscription, Veeda Clinical Research Limited IPO allotment, grey market price, and other details like the company’s background, its financial positions, its promoters, and other related things.

Veeda Clinical Research IPO is listed at a [●] premium. Check out the live share price by clicking on the below link.

Veeda Clinical Research IPO – Summary

They are one of the largest independent full-service clinical research organizations (“CRO”) in India as of March 31, 2020, based on revenue (Source: F&S Report). With over 16 years of experience, they have partnered with members of the pharmaceutical fraternity globally, to deliver efficacious clinical research solutions.

They have forayed into the pre-clinical segment by acquiring 50.10% of Bio needs, in tranches, between March and July 2021. Bio needs is a preclinical CRO providing discovery, development, and regulatory services to the pharmaceutical industry. Further, in February 2021, they established Ingenuity Biosciences Private Limited (“Ingenuity Biosciences”), which is their 50:50 joint venture with Somru BioScience Inc., (“Somru”) a Canadianbased biotechnology company, to enhance their capabilities in biosimilars.

The Promoter of this company is BASIL PRIVATE LIMITED. The lead manager to the issue is SBI Capital Markets Limited, ICICI Securities Limited, JM Financial Limited, and Systematix Corporate Services Limited, and the Registrar to this issue is Link Intime India Private Limited.

Veeda Clinical Research IPO Date

The opening and the closing date of Veeda Clinical Research IPO are not available yet.

Check out Related IPO Links:

Veeda Clinical Research IPO Subscription

The shares subscribed by the public will be updated here.

Check Veeda Clinical Research IPO LIVE Subscription

• Veeda Clinical Research IPO LIVE Bid details on BSE
• Veeda Clinical Research IPO LIVE Bid details on NSE

For the Latest Bid details click on the above links.

Veeda Clinical Research IPO Allotment Status

Here, you can find the Allotment Status of this IPO.

Allotment of Equity Shares pursuant to the Fresh Issue and transfer of the Offered Shares of the Promoter Selling Shareholders pursuant to the Offer for Sale to the successful Bidders. However, the Allotment Status is not yet disclosed.

Veeda Clinical Research Limited IPO Listing Date

Find the dates below on basis of allotment, refund, listing, and more:

Veeda Clinical Research IPO Price Band

The face value of each share is Rs.2, but the price band of the IPO is Rs.[●] 

Veeda Clinical Research IPO Size

This Initial Public Issue of X Equity Shares of Rs.2 each for cash at a price of Rs.[●]  per equity share aggregating to Rs.8,315.99 Million.

Veeda Clinical Research IPO Share Offering

Fresh Issue: The Issue (excluding the Market Maker Reservation Portion) of [●] Equity Shares of Rs.2/ each.

Issue Size: X Equity Shares of Rs.2 each, aggregating to Rs.8,315.99 Million

Open Free Demat Account Now!

Veeda Clinical Research IPO – Live Performance

The listing date of this IPO is [●]. You can check the live performance of the IPO here, only after it is listed on exchanges.

Veeda Clinical Research IPO Grey Market Premium

The Veeda Clinical Research Limited IPO Grey Market Premium price is Rs X, the Kostak rate is Rs X and the Subject to Sauda is X. 

Veeda Clinical Research IPO – Company Overview

They offer a broad range of services across most aspects of the drug development and drug launch value-chain throughout the global markets including North America, Europe, and Asia.

Their services include specialized bioanalytical services such as bioavailability and bioequivalence (“BA & BE”) studies, as well as a full suite of clinical trials including pre-clinical, early phase, and late phase clinical trials, together with related services. They have expertise in pharmacokinetics (“PK”) studies as well as trials in generic molecules, new chemical entities (“NCEs”), large molecules, and biosimilars.

They have grown from a single facility in Ahmedabad in 2004 with a total capacity of 62 beds and a capability of processing ~7,000 samples per month to four facilities at Ahmedabad and one at Mehsana, with a total capacity of 532 beds and a capability of processing ~100,000 samples per month as of March 31, 2021.

With their acquisition of Bio needs, they have now gained pre-clinical trial capabilities with two facilities in Bangalore having 99 exclusive experiment rooms designed as per international standards and self-contained chemistry, biopharma, and analytical laboratories. Further, they have also established an innovation-centric bioanalytical laboratory in Ahmedabad under Ingenuity Biosciences.

Veeda Clinical Research IPO – Financial Statements

A quick look into the past financial performance of the company to understand its performance of the business and evaluate the growth prospectus:

Financial Summary:

Earnings per Equity Share (in Million)

Further, their PAT for the period ended on March 31, 2021, and March 31, 2019, were Rs. 629.67 Million and Rs. 441.57 Million respectively.

Veeda Clinical Research IPO – Promoters

The Promoter of this company is:

1. BASIL PRIVATE LIMITED

List of Related Parties (Key Managerial Personnel)

• Ajay Tandon, Managing Director
• Nitin Jagannath Deshmukh, Chairman, and Independent Director
• Apurva Bhupendra Shah, Non-executive Director
• Kiran Vithaldas Marthak, Non-executive Director
• S.N. Vinaya Babu, Non-Executive Director
• Vivek Chhachhi, Non-executive Nominee Director

Veeda Clinical Research IPO – Promoters Holding

• Pre Issue Share Holding – %
• Pos Issue Share Holding – %

Veeda Clinical Research IPO Offer Details or Issue Details

Veeda Clinical Research IPO Issue Object

Their Company proposes to utilize the Net Proceeds towards funding the following objects:

1. Repayment/prepayment of certain indebtedness (including accrued interest) availed by their Subsidiary, Bioneeds;
2. Funding capital expenditure requirements of their Company;
3. Investment in their Subsidiary, Bioneeds for financing capital expenditure requirements;
4. Funding further acquisition of equity shares of Bioneeds;
5. Investment in their Joint Venture, Ingenuity BioSciences Private Limited through the acquisition of equity shares;
6. Funding working capital requirements of their Company; and
7. General corporate purposes.

Veeda Clinical Research IPO – Business Strategy

• Increase their presence across regulated markets in the US and the EU
• Increased focus on pre-clinical services to facilitate innovator drug development and discovery
• Expanding their presence in Biosimilars
• Strengthening their bioanalytical services
• Building on their core strength of BA & BE studies
• Enhancing their capabilities in clinical trials

Veeda Clinical Research IPO – Basis of Offer Price

The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.

Qualitative factors are:

• One of the largest independent full-service CROs in India;
• Extensive scientific competence to service a global clientele ensuring high customer centricity and satisfaction;
• Successful track record of stringent compliance culture;
• Ongoing investments to provide technology-driven CRO solutions and enhance operating efficiencies and compliance management;
• Skilled personnel and experienced professional management with a focus on continuous professional development;
• Consistent track record of robust financial performance;
• Increase their presence across regulated markets in the US and the EU;
• Increased focus on pre-clinical services to facilitate innovator drug development and discovery;
• Expanding their presence in biosimilars;
• Strengthening their bioanalytical services;
• Building on their core strength of BA & BE studies; and
• Enhancing their capabilities in clinical trials.

The relevant quantitative factors are:

Veeda Clinical Research IPO: Competitive Peers

Veeda Clinical IPO Lead Managers

Veeda Clinical IPO Registrar to offer

Veeda Research IPO – Other Details

• Statutory Auditor – S R B C & CO LLP
• Legal Counsel to the Company – Shardul Amarchand Mangaldas & Co
• Bankers to the Company –  Axis Bank Limited
  

Veeda Clinical IPO Review by Stock Brokers

Subscribe to Veeda Clinical Research IPO

Veeda Clinical Research Limited IPO News

News 1 – IPO DRHP Download

News 2 – IPO RHP Prospectus Download

Veeda Clinical Research IPO Review FAQs

Ques – What is the Issue Size of Veeda Research IPO?

Answer – The Company is making an initial public offer of NA equity shares. They vividly portray the aspects of the issue in this article. You can check the stats on the fresh issue, Offer for sale, and net issue.

Ques – What is the Price band of Veeda Clinical IPO?

Answer – The price band for this particular IPO ranges between NA. As far as the face value of the share is of concern, it is Rs.2 per share.

Ques – What is the Veeda Clinical Research IPO Open Date?

Answer – The opening and closing dates for this IPO have been updated. The IPO is set to open on NA, while the closing date is set at NA.

Ques – What is the Veeda Clinical IPO Allotment Date?

Answer – They also have the news regarding the respective allotment dates of this IPO. Basis of Allotment finalization is on NA, refund initiation is on NA, credit of shares is on NA, and share listing date is on NA.

Ques – What is the Veeda Clinical IPO Listing Date?

Answer – Shares of this company shall be listed in the exchanges NA. The date, when the listing would be done, is stagnant on NA.

Ques – Who is the Registrar of Veeda Clinical IPO?

Answer – One of the reputed registrars is managing the issue of this IPO, i.e. Link Intime India Private Limited. Their website will help you regarding the further information you are on the lookout for.

Ques – Who is the Promoter of Veeda Clinical Research IPO?

Answer – Here are the promoters of this IPO – BASIL PRIVATE LIMITED. You can refer to the RHP for further information on the promoter. You will find the link to RHP in the article.

Ques – What is the GMP of Veeda Clinical IPO?

Answer – They have obtained the GMP of this IPO and it is NA. Further insights of Kostak rate and subject to sauda or SS are as well included in this report.

Ques – Is Veeda Clinical IPO good for Investment?

Answer – They have further provided the financial status of the company in this article, from the past few years. You can refer to the same, and also check the line of operations they are into and then decide to invest in the IPO.

Ques – What is the PAT of Veeda Clinical?

Answer – They have the information of company financials, and according to that, they have the figures from the last few years to provide. PAT for the financial year 2021 in Million is 629.67, and, 2019 is 441.57.

Featured Topics